FM-FolamiR-34a

Overview

Folate-targeted miRNAs with the ability to escape the endosome to treat cancer.  FM-FolamiR-34a is the current lead molecule from the FolamiR platform.


Status


Purdue Faculty

Dr. Andrea Kasinski

Dr. Philip Low


Development Partner

LigamiR Therapeutics


Research Articles

Enhancing microRNA activity through increased endosomal release mediated by nigericin

New mechanism for release of endosomal contents: osmotic lysis via nigericin-mediated K+/H+ exchange

FolamiRs: Ligand-targeted, vehicle-free microRNA replacement therapy